Can total neoadjuvant therapy be considered an option equivalent to standard of care treatment for patients with T3N0 or T3N1 rectal adenocarcinoma?  

Or should total neoadjuvant therapy be reserved for bulkier disease (T4N2)?



Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution